Furthermore, combining radiotherapy and immunotherapy with other targeted small-molecule agents—such as STING agonists diABZI and the CDK4/6 inhibitor abemaciclib—may enhance anti-PD-1 responses in SCLC, fostering systemic antitumor immunity and warranting further clinical exploration (122, 123). The gene discussed is STING1; the disease is small cell lung carcinoma.